SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (111)10/10/2001 10:03:23 AM
From: tuck  Read Replies (1) | Respond to of 897
 
Not sure where the hysteria will stop, but NGEN, which I own and just wrote calls against, has almost doubled on news of a $1.5 million contract with USAMRIID. It was undervalued, IMO, but this is an over reaction to a small win, however hot the field. If you can figure out the top, this should be good for several points retreat once reality reasserts itself. I hate to put a stock I own here, but . . .

Cheers, Tuck



To: scaram(o)uche who wrote (111)10/15/2001 8:35:32 AM
From: rkrw  Read Replies (1) | Respond to of 897
 
<<<Moreover, I wouldn't assume that Adcon-L will ever hit the market again. It clearly makes second surgeries a breeze relative to those where it wasn't used and adhesions need to be removed/navigated, but efficacy has always been difficult to demonstrate by other measures.>>>

Prescient commentary.

I guess it really took an eraser and a pencil to demonstrate statistical significance <g>


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News